Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Biofrontera (BFRI) Common Equity: 2020-2024

Historic Common Equity for Biofrontera (BFRI) over the last 5 years, with Dec 2024 value amounting to $4.4 million.

  • Biofrontera's Common Equity fell 146.67% to -$2.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$2.6 million, marking a year-over-year decrease of 146.67%. This contributed to the annual value of $4.4 million for FY2024, which is 7.51% down from last year.
  • According to the latest figures from FY2024, Biofrontera's Common Equity is $4.4 million, which was down 7.51% from $4.8 million recorded in FY2023.
  • Biofrontera's Common Equity's 5-year high stood at $23.9 million during FY2022, with a 5-year trough of $4.4 million in FY2024.
  • Its 3-year average for Common Equity is $11.0 million, with a median of $4.8 million in 2023.
  • Its Common Equity has fluctuated over the past 5 years, first spiked by 110.60% in 2022, then tumbled by 79.93% in 2023.
  • Yearly analysis of 5 years shows Biofrontera's Common Equity stood at $5.8 million in 2020, then surged by 94.54% to $11.3 million in 2021, then spiked by 110.60% to $23.9 million in 2022, then tumbled by 79.93% to $4.8 million in 2023, then declined by 7.51% to $4.4 million in 2024.